Supplemental material
Online Table 1: DATECAN Pancreatic cancer experts
Full Name / SPECIALTY / Institution / City / COUNTRYCoordinating Committee (CC) / Bonnetain, F / Methodology / Biostatistics / University Hospital of Besançon and GERCOR / Besançon / France
Collette L / Methodology / Biostatistics / European Organization of Research and Treatment of Cancer / Brussels / Belgium
Dousseau A / Methodology / Biostatistics / Institut Bergonié, Comprehensive Cancer Center / Bordeaux / France
Steering Committee (SC) / Bonsing B / oncology / Leiden University Medical Cente / Leiden / Netherlands
Conroy T / Oncology / Center Alexis Vautrin Comprehensive Cancer Center / Nancy / France
Glimelius B / Radiation Oncology / Uppsala University hospital / Uppsala / Sweden
Haustermans K / Radiation Oncology / University hospital / Leuven / Belgium
Lacaine L / Surgery / Tenon hospital / Paris / France
Van Laethem JL / Medical Oncology / Erasme Hospital / Brussels / Belgium
Rating Committee (RC) / Aparicio T / Gastroenterology / Avicenne hospital / Bobigny / France
Aust D / pathology / University Hospital Carl-Gustav-Carus / Dresden / Germany
Bassi C / Surgical oncology / Hospital of 'G.B.Rossi', University of Verona / Verona / Italy
Berger V / Oncology and methodology / Centre Paul Papin, Comprehensive Cancer Center / Angers / France
Chamorey E / Methodology / Biostatistics / Centre Antoine Lacassagne, Comprehensive Cancer Center / Nice / France
Chibaudel B / Medical oncology / Hôpital Saint-Antoine / Paris / France
Dahan L / Gastroenterologys / Hopital la Timone / Marseille / France
De Gramont E / Medical oncology / Hôpital Saint-Antoine / Paris / France
Delpero JR / Surgical oncology / Institut Paoli CalmetteComprehensive Cancer Center / Marseille / France
Dervenis C / Surgery / Agia Olga Hospital / Athens / Greece
Ducreux M / Medical oncology / Institut Gustave Roussy Comprehensive Cancer Center / Villejuif / France
Gal J / Statisticien / Centre Antoine Lacassagne, Comprehensive Cancer Center / Nice / France
Gerber E / Radiotherapy / Institut fuer Radioonkologie / Vienna / Austria
Ghaneh P / Surgery / Royal Liverpool Hospital / Liverpool / UK
Hammel P / gastroenterology / Beaujon Hospital / Paris / France
Hendlisz A / Medical oncology / Jules Bordet Institute / Brussels / Belgium
Jooste, V / Epidemiology / Cancer Registry / Dijon / France
Labianca R / Medical oncology / Ospedali Riuniti di Bergamo / Bergamo / Italy
Latouche A / Statistics / Centre for Research in Epidemiology and Population Health, Inserl U1018, / Villejuif / France
Lutz M / Gastroenterology / Caritas Hospital / Saarbrucken / Germany
Macarulla T / Medical oncology / Vall d'Hebron University Hospital / Barcelona / Spain
Malka D / Medical oncology / Institut Gustave Roussy Comprehensive Cancer Center / Villejuif / France
Mauer M / biostatistics / European Organization of Research and Treatment of Cancer / Brussels / Belgium
Mitry E / Gastroenterology / Institut Curie - Hôpital René Huguenin / Saint Cloud / France
Neoptolemos J / Surgical oncology / University of Liverpool and Royal Liverpool University Hospital / Liverpool / UK
Pessaux P / Surgery / university hospital / Strasbourg / France
Sauvanet A / Surgery / Beaujon Hospital / Paris / France
Tabernero J / Medical oncology / Vall d'Hebron University Hospital / Barcelona / Spain
Taieb J / Gastroenterology / Georges Pompidou European hospital / Paris / France
van Tienhoven / Radiotherapy / Academisch Medisch Centrum / Amsterdam / Netherlands
Peer-review committee / Carine Bellera / Biostatistics/
Methodology / Institut Bergonié, Comprehensive Cancer Center and INSERM CIC-EC7, France / Bordeaux / France
Simone Mathoulin-Pélissier / Institut Bergonié, Comprehensive Cancer Center and INSERM CIC-EC7, France / Bordeaux / France
Sophie Gourgou / Biostatistical Unit, Centre Val d’Aurelle, Comprehensive Cancer Centre, Montpellier, France / Montpellier / France
Online table 2 Report of the 1st and 2nd round results of Cancer-specific survival
In green: consensus for including event
In pink: consensus for not including event
White or grey: no consensus
Online Table 3: Report of the 1st and 2nd round results of Disease Free Survival
In green: consensus for including event
In pink: consensus for not including event
White, blue or grey: no consensus
Online Table 4: Report of the 1st and 2nd round results of Relapse Free Survival
In green: consensus for including event
In pink: consensus for not including event
White or grey: no consensus
Online Table 5: Report of the 1st and 2nd round results of Loco Regional Relapse Free Survival
In green: consensus for including event
In pink: consensus for not including event
White or grey: no consensus
Online Table 6: Report of the 1st and 2nd round results of time to local recurrence
In green: consensus for including event
In pink: consensus for not including event
White or grey: no consensus
Online Table 7: Report of the 1st and 2nd round results of Distant Metastasis Free Survival (DMFS)
In green: consensus for including event
In pink: consensus for not including event
White or grey: no consensus
Online Table 8: Report of the 1st and 2nd round results of Time to Treatment Failure (TTF)
In green: consensus for including event
In pink: consensus for not including event
White or grey: no consensus
Online Table 9: Report of the 1st and 2nd round results of Failure Free Survival (FFS)
In green: consensus for including event
In pink: consensus for not including event
White, blue or grey: no consensus
Online Table 10: Report of the 1st and 2nd round results of Progression Free Survival (PFS)
In green: consensus for including event
In pink: consensus for not including event
White, blue or grey: no consensus
Online Table 11 : Report of the 1st and 2nd round results of Time to Progression (TTP)
In green: consensus for including event
In pink: consensus for not including event
White or grey: no consensus
Online Table 12: Report of the 1st and 2nd round results of Time to Local Progression (TLP)
In green: consensus for including event
In pink: consensus for not including event
White or grey: no consensus
Online Table 13: Report of the 1st and 2nd round results of Metastatic Progression-free survival (MPFS)
In green: consensus for including event
In pink: consensus for not including event
White or grey: no consensus
Online Table 14: Report of the 1st and 2nd round results of time to performance status deterioration
In green: consensus for including event
In pink: consensus for not including event
White or grey: no consensus
Online Table 15: Report of the 1st and 2nd round results of time to Quality of life deterioration
In green: consensus for including event
In pink: consensus for not including event
White or grey: no consensus
Page | 1